Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4862996
Max Phase: Preclinical
Molecular Formula: C56H76F15N13O16
Molecular Weight: 902.16
Molecule Type: Unknown
Associated Items:
ID: ALA4862996
Max Phase: Preclinical
Molecular Formula: C56H76F15N13O16
Molecular Weight: 902.16
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NCCN1CCN(CCCC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C46H71N13O6.5C2HF3O2/c1-32(42(62)55-38(14-7-8-20-47)45(65)53-33(2)60)52-44(64)37(15-9-21-51-46(48)49)50-22-26-57-29-27-56(28-30-57)23-10-11-34-18-24-58(25-19-34)31-41(61)59-39-16-5-3-12-35(39)43(63)54-36-13-4-6-17-40(36)59;5*3-2(4,5)1(6)7/h3-6,12-13,16-17,32,34,37-38,50H,7-11,14-15,18-31,47H2,1-2H3,(H,52,64)(H,54,63)(H,55,62)(H4,48,49,51)(H,53,60,65);5*(H,6,7)/t32-,37-,38-;;;;;/m0...../s1
Standard InChI Key: LFYXFYWCCDXVIA-YFUOVJHYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 902.16 | Molecular Weight (Monoisotopic): 901.5650 | AlogP: 1.03 | #Rotatable Bonds: 23 |
Polar Surface Area: 263.45 | Molecular Species: BASE | HBA: 12 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 19 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 6.97 | CX Basic pKa: 13.51 | CX LogP: -1.10 | CX LogD: -6.87 |
Aromatic Rings: 2 | Heavy Atoms: 65 | QED Weighted: 0.04 | Np Likeness Score: -0.32 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):